- In patients with relapsed/refractory follicular lymphoma (R/R FL), R/R germinal center B-cell diffuse large B-cell lymphoma (GCB DLBCL), or R/R non-GCB DLBCL, the addition of durvalumab to ibrutinib failed to meaningfully increase efficacy.
Why this matters
- Ibrutinib is known to increase cytotoxic T-cell activation and to enhance proinflammatory cytokine secretion; such effects should theoretically work synergistically with programmed death cell-1 (PD-1) inhibition.
- Phase 2 study to investigate ibrutinib+durvalumab in patients with R/R FL (n=27), R/R GCB DLBCL (n=17), non-GCB DLBCL (n=16), or unspecified DLBCL (n=2).
- Median patient age, 60 (range, 22-82) years.
- Funding: Pharmacyclics LLC, an AbbVie Company.
- Overall response rate (ORR):
- R/R FL: 26% (95% CI, 11%-46%).
- GCB DLBCL: 13% (95% CI, 2%-38%).
- Non-GCB DLBCL: 38% (95% CI, 15%-65%).
- Median PFS:
- R/R FL: 10.2 months.
- GCB DLBCL: 2.9 months.
- Non-GCB DLBCL: 4.1 months.
- Median OS:
- R/R FL: not evaluable.
- GCB DLBCL: 5.5 months.
- Non-GCB DLBCL: 7.3 months.
- 56% of patients overall experienced grade 3-4 adverse events (AEs).
- Most common grade 3-4 treatment-emergent AEs included neutropenia (21%) and dyspnea (10%).
- Open-label study design.